Cohen is principle investigator and codirector of the International
Center of Traditional Chinese Medicine for Cancer, a collaborative
project between the University of Texas M.D. Anderson Cancer Center
and Fudan University Cancer Hospital in China. The collaboration
is partially funded by NCI.
Cohen described the use of western medical tools, such as medical
imaging studies, that are guiding traditional Chinese medicine
treatments at Fudan Cancer Hospital. He gave insight into some
studies, including examination of huachansu (a bufotoxin excreted
from parotid glands of Bufo toads) in preclinical studies at M.D.
Anderson and in a phase I clinical study in advanced hepatocellular
carcinoma, non-small cell lung cancer and pancreatic cancer at
Fudan Cancer Hospital.
Huachansu is an important component of cancer treatment in China.
Cohen discussed efforts to understand bufotoxin mechanisms of action,
as well as quality control for this natural product. He also discussed
some of the acupuncture and bio-behavioral projects administered
through the international center and highlighted some unique opportunities
that have come about as a result of this partnership. Opportunities
include research training, long-term exchange between the two institutions
and traditional Chinese medicine training.
Cohen is director of the integrative medicine program in the division
of cancer medicine at M.D. Anderson. A video of his presentation
is available at http://cancer.gov/cam.